Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

SILO

SILO Pharma Inc

Dec 20 • 04:00PM ET

0.8780

Dollar change +0.0431
Percentage change 5.16	%

Healthcare • Biotechnology • USA • NASD

Peers: CMPS ATAI MNMD CYCN AVXL GHRS RLMD NERV MNOV RLX

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.19	Insider Own	4.30%	Shs Outstand	4.48M	Perf Week	5.14%
Market Cap	4.14M	Forward P/E	-	EPS next Y	-	Insider Trans	3.84%	Shs Float	4.29M	Perf Month	-7.10%
Income	-3.78M	PEG	-	EPS next Q	-	Inst Own	7.53%	Short Float	3.97%	Perf Quarter	-15.58%
Sales	0.07M	P/S	59.19	EPS this Y	-	Inst Trans	-	Short Ratio	0.60	Perf Half Y	-18.33%
Book/sh	1.51	P/B	0.58	EPS next Y	-	ROA	-42.31%	Short Interest	0.17M	Perf Year	-43.35%
Cash/sh	1.70	P/C	0.52	EPS next 5Y	-	ROE	-52.02%	52W Range	0.77 - 4.50	Perf YTD	-39.03%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-4.01%	ROI	-55.78%	52W High	-80.49%	Beta	-
Dividend TTM	-	Quick Ratio	7.91	Sales past 5Y	-19.76%	Gross Margin	-844.89%	52W Low	14.03%	ATR (14)	0.10
Dividend Ex-Date	-	Current Ratio	7.91	EPS Y/Y TTM	11.90%	Oper. Margin	-5625.46%	RSI (14)	44.24	Volatility	12.76% 11.35%
Employees	3	Debt/Eq	0.00	Sales Y/Y TTM	0.00%	Profit Margin	-5247.34%	Recom	1.00	Target Price	10.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-1.65%	Payout	-	Rel Volume	0.33	Prev Close	0.83
Sales Surprise	0.00%	EPS Surprise	0.00%	Sales Q/Q	0.00%	Earnings	-	Avg Volume	284.09K	Price	0.88
SMA20	-4.15%	SMA50	-15.81%	SMA200	-38.52%	Trades		Volume	92,466	Change	5.16%

Dec-19-24 07:40AM	Silo Pharma initiates pharmacokinetic, tolerability study for SP-26 (TipRanks)
Dec-18-24 07:35AM	Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia (GlobeNewswire) -15.33%
Nov-29-24 08:05AM	Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management (GlobeNewswire) +11.11%
Nov-18-24 08:40AM	Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders (GlobeNewswire) -12.39%
Oct-31-24 08:35AM	Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant (GlobeNewswire)
06:35AM	Loading…
Sep-10-24 06:35AM	Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD (GlobeNewswire) -13.01%
Aug-14-24 02:30PM	Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic (GlobeNewswire) +9.60%
Aug-07-24 08:13AM	Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide (GlobeNewswire) -13.24%
Jul-26-24 08:20AM	Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference (GlobeNewswire) +9.95%
Jul-22-24 04:45PM	Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire)
Jul-19-24 08:01AM	Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -29.11%
Jul-18-24 08:25AM	Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15 (GlobeNewswire) +54.22%
Jul-16-24 08:00AM	Why Is Silo Pharma (SILO) Stock Up 123% Today? (InvestorPlace) +123.36%
07:43AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
06:30AM	Silo Pharma Secures Exclusive Global License for Alzheimer's Therapeutic (GlobeNewswire)
08:45AM	Loading…
Jul-08-24 08:45AM	Silo Pharma Announces Exclusive, Global License for Lead Candidate SPC-15 Targeting PTSD and Stress-Induced Anxiety Disorders (GlobeNewswire) -5.19%
Jun-26-24 08:50AM	Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and Anxiety (GlobeNewswire) -6.48%
Jun-07-24 08:18AM	Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia (GlobeNewswire)
Jun-06-24 04:50PM	Silo Pharma Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire)
Jun-05-24 08:00AM	Silo Pharma Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -46.67%
Jun-04-24 08:41AM	Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety (GlobeNewswire) +10.84%
May-21-24 08:45AM	Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention (GlobeNewswire) +7.39%
May-14-24 08:45AM	Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine (GlobeNewswire)
Apr-23-24 08:15AM	Silo Pharma Announces Positive Results for Intranasal PTSD Treatment (GlobeNewswire) -10.55%
Apr-14-24 03:00PM	10 Micro-Cap Healthcare Stocks Insiders Are Buying (Insider Monkey)
Apr-10-24 08:11AM	Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer's Disease Therapeutic (GlobeNewswire)
Apr-02-24 03:12PM	Hedge Fund and Insider Trading News: Ray Dalio, Steven Tananbaum, Steve Cohen, Crispin Odey, Ken Griffin, Third Point LLC, Westlake Chemical Partners LP (WLKP), and More (Insider Monkey)
Mar-20-24 08:30AM	Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic (GlobeNewswire)
Mar-18-24 07:15AM	Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain (GlobeNewswire)
Feb-28-24 08:25AM	Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD (GlobeNewswire)
08:45AM	Loading…
Feb-14-24 08:45AM	Silo Pharma's SP-26 Ketamine Implant Demonstrates Successful Drug Delivery (GlobeNewswire) +5.62%
Feb-01-24 10:00AM	Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology (GlobeNewswire)
Jan-24-24 08:55AM	Silo Pharma Announces Positive Results in Alzheimer's Disease Study (GlobeNewswire) +5.71%
Jan-04-24 08:55AM	Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD (GlobeNewswire)
Dec-28-23 08:25AM	Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia (GlobeNewswire) -11.00%
Nov-21-23 08:01AM	Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD (GlobeNewswire) +12.93%
Nov-08-23 08:11AM	Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD (GlobeNewswire)
Oct-16-23 08:11AM	Silo Pharma's SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis (GlobeNewswire) -7.28%
Oct-11-23 08:35AM	Silo Pharma Initiates Human Factor Study of SPC-15 for the Treatment of PTSD (GlobeNewswire)
Sep-20-23 08:28AM	Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA (GlobeNewswire)
Sep-12-23 08:50AM	Silo Pharma Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD (GlobeNewswire)
Aug-10-23 08:50AM	Silo Pharma Engages Clarivate for Intellectual Property and Patent Management (GlobeNewswire)
Aug-08-23 08:30AM	Silo Pharma Reaches Positive Milestone with Nasal Formulation of SPC-15 For Anxiety, PTSD, and Stress-Related Disorders (GlobeNewswire)
Jun-23-23 09:00AM	Psychedelics Company Silo Pharma Working On Time-Release And Dosage Ketamine Implant And Topical, Hoping To Deliver Steady Pain Relief For Four Million Fibromyalgia Sufferers (ACCESSWIRE)
Jun-21-23 09:00AM	Silo Pharmas SPU-21 Treatment for Autoimmune Disease Awarded U.S. Patent (GlobeNewswire)
Jun-13-23 08:05AM	Silo Pharma Signs Agreement to Develop First-in-Class Ketamine Implant Therapeutic (GlobeNewswire) -5.25%
Jun-02-23 08:50AM	Silo Pharma Announces Participation on Webull Corporate Communications Service Platform (GlobeNewswire)
May-30-23 09:00AM	Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21 (GlobeNewswire)
May-09-23 08:05AM	Silo Pharmas SPC-15 Awarded U.S. Patent Protecting Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimers Disease (GlobeNewswire)
Apr-24-23 08:15AM	Silo Pharma to Present at Psychedelic Drug Development Conference (GlobeNewswire)
Apr-19-23 09:00AM	Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders (GlobeNewswire)
Mar-27-23 09:00AM	Silo Pharma Announces filing of Patent for Treatment of Fibromyalgia (GlobeNewswire)
Mar-15-23 08:40AM	Silo Pharma Announces Positive Results from IND-Enabling Study of SP-26 for Fibromyalgia (GlobeNewswire) -5.45%
Feb-13-23 08:35AM	Silo Pharma Announces Filing of Patent for Treatment of Alzheimers (GlobeNewswire) +14.86%
Feb-02-23 08:50AM	Silo Pharma Announces Expansion of Intellectual Property Portfolio (GlobeNewswire) +16.35%
Jan-31-23 07:45AM	Silo Pharma Announces Stock Repurchase Program (GlobeNewswire) +6.37%
Jan-10-23 10:15AM	Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation (GlobeNewswire)
Dec-30-22 08:10AM	Silo Pharma Announces Positive Study Results of SPU- 21 for Arthritis (GlobeNewswire)
Dec-01-22 09:00AM	Silo Pharma Issues Letter to Shareholders Detailing Progress on Pipeline Assets Combining Traditional Therapeutics with Psychedelic Medicine (GlobeNewswire)
Nov-21-22 07:45AM	Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human Tissue (GlobeNewswire)
Nov-11-22 08:15AM	Silo Pharma Achieves New Milestone for SP-26 Therapeutic -Initiates IND Enabling Study of Topical Ketamine Formulation (GlobeNewswire) +6.75%
Oct-26-22 09:00AM	Silo Pharma to Discuss Mainstream Pharma and Psychedelics at Wonderland Miami Conference (GlobeNewswire)
Oct-20-22 08:05AM	Silo Pharma Announces Data Supporting Therapeutic Potential of SPC-14 for Alzheimers Disease in Pre-Clinical Study (GlobeNewswire) -12.97%
Oct-18-22 07:15AM	Silo Pharma extends research pact for Alzheimers and Stress Induced Anxiety Therapeutics (GlobeNewswire)
Oct-10-22 08:05AM	Silo Pharma Initiates Toxicity Study of its Proprietary Ketamine Formulation for Treatment of Fibromyalgia (GlobeNewswire)
Oct-06-22 08:20AM	Silo Pharma to Present at the Dawson James Small Cap Growth Conference on October 12 (GlobeNewswire)
Oct-03-22 09:47AM	Silo Pharma Initiates FDA Pre-Investigational New Drug (IND) Package for Time-Released Ketamine Technology (GlobeNewswire)
Sep-30-22 08:30AM	Silo Pharma Announces Closing of $5.75 Million Public Offering of Common Stock, Nasdaq Listing, and Full Exercise of Underwriters Over-Allotment Option (GlobeNewswire)
Sep-27-22 09:05AM	Silo Pharma Announces Uplisting to Nasdaq Capital Market and Pricing of $5 Million Public Offering of Common Stock (GlobeNewswire) -24.56%
Sep-15-22 08:00AM	Silo Pharma Announces Implementation of 1-for-50 Reverse Stock Split in Preparation for Planned Uplisting to Nasdaq (GlobeNewswire)
Jul-27-22 08:15AM	Silo Pharma Announces Positive Results from its Topically Administered Formulation of Ketamine (GlobeNewswire)
Jul-12-22 11:23AM	Silo Pharma Announces Positive Results in Subcutaneous Delivery of its Novel Liposomes to Treat Arthritic Patients (GlobeNewswire) +14.90%
Jun-23-22 08:05AM	Silo Pharma Expands License Agreement and Patent Portfolio (GlobeNewswire) -14.29%
May-19-22 08:11AM	Silo Pharma Announces Successful Dosing of Patients Suffering from Parkinsons Disease in Psilocybin Study (GlobeNewswire)
May-18-22 08:17AM	IBN (InvestorBrandNetwork) Announces Latest Episode of The Bell2Bell Podcast featuring Eric Weisblum, CEO of Silo Pharma Inc. (GlobeNewswire)
Apr-20-22 08:10AM	Silo Pharma Produces SPU-21 Liposomes for Rheumatoid Arthritis Study (GlobeNewswire) +6.45%
Mar-31-22 08:10AM	Silo Pharma Enters into Agreement with Contract Research Organization for Pharmacokinetic Study (GlobeNewswire)

Silo Pharma, Inc. is a developmental stage biopharmaceutical company, which engages in the merging of traditional therapeutics with psychedelic research. It seeks to acquire and develop intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs. The company was founded by Eric Weisblum on July 13, 2010 and is headquartered in Sarasota, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Weisblum Eric	CEO and President	Dec 13 '24	Buy	0.84	2,500	2,097	187,932	Dec 16 05:00 PM
Weisblum Eric	CEO and President	Nov 20 '24	Buy	0.95	2,500	2,375	182,932	Nov 22 04:16 PM
Weisblum Eric	CEO and President	Nov 22 '24	Buy	0.90	2,500	2,250	185,432	Nov 22 04:16 PM
Weisblum Eric	CEO and President	Jun 12 '24	Buy	1.11	4,438	4,926	180,432	Jun 13 01:19 PM
Weisblum Eric	CEO and President	Jun 11 '24	Buy	1.08	562	607	175,994	Jun 13 01:19 PM
Weisblum Eric	CEO and President	Apr 04 '24	Buy	1.96	600	1,176	175,032	Apr 08 04:00 PM
Weisblum Eric	CEO and President	Apr 05 '24	Buy	2.03	400	812	175,432	Apr 08 04:00 PM
Weisblum Eric	CEO and President	Mar 28 '24	Buy	1.94	3,408	6,612	173,332	Apr 01 06:15 PM
Weisblum Eric	CEO and President	Apr 01 '24	Buy	1.91	1,100	2,101	174,432	Apr 01 06:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SILO

SILO Pharma Inc

Upgrade your FINVIZ experience